Calcitonin vs. Parathyroid Hormone Explained

Calcitonin and parathyroid hormone (PTH) are often described as opposites in the regulation of blood calcium, and at the broadest level that framing holds up: PTH raises calcium, calcitonin lowers it. But the two hormones differ dramatically in their importance, their mechanisms, and the roles they play in clinical medicine. PTH is the dominant force in day-to-day calcium balance, while calcitonin’s physiological significance in adults remains surprisingly debatable, even after decades of research.

Where Each Hormone Comes From

PTH is produced by the parathyroid glands, four tiny nodules typically embedded in the back surface of the thyroid gland. These glands monitor circulating calcium levels and release PTH when calcium drops too low.¹ The sensing mechanism depends on a receptor called the calcium-sensing receptor, which sits on parathyroid cells and detects even small shifts in calcium concentration. When calcium rises, the receptor signals the gland to dial back PTH secretion; when calcium falls, PTH floods into the bloodstream.²

Calcitonin comes from a completely different cell type: the parafollicular C cells scattered within the thyroid gland itself. When blood calcium climbs above normal, C cells release calcitonin to help bring it back down. These cells are embryologically distinct from the thyroid’s main hormone-producing follicular cells, and the gene that encodes calcitonin is also responsible, through alternative processing, for producing a separate peptide called CGRP in nerve tissue.³ CGRP has its own distinct role as a vasodilator and pain-signaling molecule. That dual-use gene is one reason calcitonin research has sprawled into unexpected territory, including migraine treatment.

How They Affect Bone

The skeleton is the body’s largest calcium reservoir, and both hormones influence whether calcium flows into bone or out of it, but they do so through different cell targets and in opposite directions.

PTH acts primarily on osteoblasts, the cells that build bone. When PTH lands on an osteoblast, one of its effects is to ramp up production of a signaling molecule called RANKL, which in turn stimulates the formation and activity of osteoclasts, the cells that break bone down and release its stored calcium into the blood.⁴ Experiments in mice confirm that injecting PTH increases not only bone formation but also osteoclast activity and circulating RANKL levels.⁵ The net result, when PTH is chronically elevated, is calcium leaving bone and entering the blood.

Calcitonin takes the opposite approach: it acts directly on osteoclasts to shut them down. Rather than working through an intermediary cell, calcitonin binds to receptors on the osteoclast surface and inhibits both their movement and their bone-dissolving activity.⁶ The effect is a reduction in bone breakdown, which means more calcium stays locked in the skeleton and blood calcium drifts downward.⁷

There is an important catch with calcitonin’s bone effects, though. Osteoclasts “escape” from calcitonin’s grip over time. Research has shown that osteoclasts initially frozen in place by calcitonin gradually resume their resorptive activity, and this escape reflects the same cells restarting rather than new osteoclasts taking their place.⁸ This escape phenomenon is one reason calcitonin’s long-term impact on bone is limited compared to PTH’s persistent influence.

What Each Hormone Does in the Kidneys

The kidneys are the other major site where PTH exerts control over mineral balance. PTH has two simultaneous effects there: it reduces the amount of calcium lost in urine by promoting calcium reabsorption, and it increases the excretion of phosphate by pulling phosphate-transporting proteins out of the kidney tubule lining.⁹ Both actions serve the same goal. Holding onto calcium and dumping phosphate raises the ratio of free calcium in the blood, because calcium and phosphate tend to bind each other.

Calcitonin has the opposite renal effect: it promotes calcium excretion into the urine, further contributing to a drop in blood calcium levels. However, the magnitude of calcitonin’s kidney action in humans appears modest compared to PTH’s. People who have had their thyroid glands surgically removed, and therefore produce essentially no calcitonin, generally maintain normal calcium levels without supplementation. That clinical observation has long fueled skepticism about how much calcitonin really matters in adult human physiology.

The Vitamin D Connection

PTH does not work alone to raise blood calcium. One of its most important downstream effects is activating vitamin D. The vitamin D you get from sunlight or supplements is biologically inert until it goes through two chemical conversions. The second and final activation step happens in the kidneys, where an enzyme converts the precursor into calcitriol, the active form of vitamin D.¹⁰ PTH is a powerful stimulator of that enzyme.¹¹

Once calcitriol is produced, it boosts calcium absorption from the intestines, providing a whole additional source of calcium beyond bone and kidneys. The relationship between PTH and vitamin D also includes a feedback loop: calcitriol suppresses PTH secretion, so when vitamin D levels are adequate the parathyroid glands ease off.¹² This is why chronic vitamin D deficiency can lead to persistently elevated PTH, a condition called secondary hyperparathyroidism, because the feedback brake never engages.

Calcitonin has no comparable role in vitamin D activation. This asymmetry is one of the clearest indicators of how much more central PTH is to the whole calcium-regulation system. PTH coordinates bone, kidney, and gut calcium handling through vitamin D; calcitonin primarily just taps the brakes on osteoclasts.

Phosphate Balance and FGF23

Calcium and phosphate metabolism are tightly linked because the two minerals interact chemically. High levels of both at the same time can lead to dangerous deposits in soft tissues. PTH addresses this by pushing the kidneys to excrete phosphate while retaining calcium, keeping the two minerals in a safe balance.

The traditional picture of phosphate regulation centered on PTH and vitamin D, but researchers have since identified a third major player: FGF23, a hormone produced primarily by bone cells. FGF23 inhibits phosphate reabsorption in the kidneys and also suppresses calcitriol production, acting as a counterweight to PTH’s vitamin D-boosting effect.¹³ PTH itself can stimulate FGF23 production in bone, creating a cross-talk loop between the parathyroid glands and the skeleton that fine-tunes phosphate levels.¹⁴

Calcitonin does not have a well-defined role in phosphate regulation comparable to PTH or FGF23. This three-way network of PTH, vitamin D, and FGF23 governs the majority of phosphate handling in the body, and it is the system that goes haywire in chronic kidney disease, where failing kidneys cannot respond properly to any of the three signals.

Circadian Rhythms in Calcium Regulation

If you have ever had your blood calcium or PTH tested, the time of day your blood was drawn matters more than most people realize. PTH follows a distinct daily cycle. Levels stay relatively flat during the daytime but begin to climb after about 8 p.m., peak between 2 and 4 a.m., and return to baseline by morning.¹⁵ Calcium and PTH swing in opposite directions through the night, while PTH and phosphate oscillate together, and the swings are not trivial: the amplitude can span a quarter to over 40 percent of the normal reference range.¹⁶

This nocturnal PTH surge likely explains why most bone resorption also happens at night. For clinicians diagnosing parathyroid disorders, the implication is that an afternoon blood sample might miss a borderline elevation that would have been obvious at 3 a.m. Standardized morning fasting draws are partly an attempt to control for this variation, though they still catch PTH on its way down rather than at its peak.

When Things Go Wrong

Disorders of PTH are common and clinically significant. In primary hyperparathyroidism, one or more parathyroid glands produce too much PTH, leading to elevated blood calcium, weakened bones, kidney stones, and a range of vague symptoms including fatigue and cognitive fog. In hypoparathyroidism, too little PTH causes dangerously low calcium, which can trigger muscle spasms, seizures, and cardiac problems. The ratio of calcium to phosphate in the blood can help distinguish these two conditions: values above about 2.55 point toward hyperparathyroidism, while values below about 1.78 suggest hypoparathyroidism.¹⁷

Calcitonin disorders, by contrast, rarely produce calcium-related symptoms. The one major exception is medullary thyroid carcinoma, a cancer of the C cells that produce calcitonin. This cancer spills large amounts of calcitonin into the blood, but the clinical problem is the cancer itself, not usually a calcium imbalance. Calcitonin blood levels serve as a highly useful tumor marker: basal concentrations above roughly 60 to 100 pg/mL strongly suggest medullary thyroid carcinoma.¹⁸ A meta-analysis of studies using routine calcitonin screening in patients with thyroid nodules found that the test had a sensitivity and specificity both around 99 percent for catching this cancer, making it one of the best blood-based cancer screens available.¹⁹

How Each Hormone Is Used as a Treatment

Both hormones have been turned into drugs, though for different reasons and with very different trajectories.

PTH-based therapy is one of the few treatments that actually builds new bone rather than just slowing its loss. Teriparatide, a synthetic fragment of PTH, is prescribed as a daily injection for severe osteoporosis. The paradox here is striking: chronically high PTH destroys bone, yet intermittent daily pulses of the same hormone stimulate bone formation.²⁰ Research confirms that these intermittent pulses reduce fracture risk in postmenopausal women with osteoporosis, and the effect involves changes in the bone-remodeling cycle that tip the balance toward construction over demolition.²¹ The precise cellular mechanism behind this anabolic window remains an open question, which is unusual for a drug that has been in clinical use for over two decades.

Salmon calcitonin was once a mainstay of osteoporosis treatment, delivered as a nasal spray or injection. It was attractive because it could reduce bone loss and also had analgesic properties for vertebral fracture pain. However, its clinical decline has been steep. One problem is the escape phenomenon already described: osteoclasts stop responding over time. Another is that many patients develop antibodies against the salmon-derived peptide, which can neutralize the drug entirely. Studies found that within six months of starting treatment, roughly a third or more of patients had developed such antibodies, and in some cases these neutralizing antibodies reduced the drug’s biological activity to a fraction of normal levels.²² Rates of clinically meaningful resistance have been estimated at 25 to 45 percent of patients treated for six months or longer.²³ Combined with safety concerns about a possible small increase in cancer risk with long-term use, calcitonin has been largely supplanted by newer osteoporosis drugs.

Calcium Regulation During Pregnancy and Breastfeeding

Pregnancy and breastfeeding are situations where the normal PTH-centered model of calcium regulation gets rewritten. The developing fetus and nursing infant need enormous amounts of calcium, and the mother’s body meets that demand through mechanisms that operate largely independently of PTH.

During pregnancy, calcitriol production increases substantially, but this rise is driven by factors other than PTH. A related molecule called PTH-related peptide, or PTHrP, produced by the placenta and other tissues, rises progressively throughout gestation and may help drive renal calcitriol synthesis.²⁴ During breastfeeding, the system shifts again: high PTHrP from the mammary gland, combined with the low-estrogen state of lactational amenorrhea, promotes bone resorption to supply calcium for milk production. PTH itself may actually be suppressed during these periods. The whole arrangement is a reminder that the textbook “PTH up, calcium up; calcitonin up, calcium down” framework, while correct as a baseline, does not capture the full picture in every physiological state.

An Evolutionary Perspective on the Asymmetry

The disparity in importance between these two hormones makes more sense in evolutionary context. In fish, calcitonin is critical because aquatic vertebrates face constant calcium influx from calcium-rich water and need a robust mechanism to prevent hypercalcemia. As vertebrates moved onto land, the challenge shifted: calcium became harder to obtain from the environment, and the dominant problem became getting enough of it rather than fending off excess. PTH, along with vitamin D, became the central axis for pulling calcium from bone, retaining it in the kidneys, and absorbing it from food. From amphibians onward, bone became an increasingly dynamic tissue, with regulated resorption driven primarily by PTH and active vitamin D acting on osteoclasts.²⁵

Calcitonin was retained through evolution, but its role in terrestrial vertebrates appears to have diminished. The fact that people without thyroid glands, and therefore without C cells, show no obvious calcium abnormality underscores how far calcitonin has fallen from its ancestral importance. Its retention may relate partly to its alternative gene product, CGRP, which plays active roles in vasodilation and pain signaling and would keep evolutionary pressure on the gene even if the calcitonin peptide itself became physiologically marginal.

Why the “Opposite Hormones” Framing Falls Short

Textbooks often present calcitonin and PTH as a matched pair of antagonists, equal and opposite forces keeping calcium in a narrow range. This framing is tidy and useful for exams, but it overstates calcitonin’s role in daily calcium regulation and understates how much more PTH does. PTH coordinates bone resorption, kidney reabsorption, phosphate excretion, and vitamin D activation in a single integrated response. Calcitonin acts on one target, the osteoclast, and even that effect fades over time. The real “opposite” of PTH in calcium regulation may be the calcium-sensing receptor itself, which detects rising calcium and simply tells the parathyroid glands to stop releasing PTH. The system’s main thermostat runs almost entirely through PTH and its off-switch, not through a separate lowering hormone.

Where calcitonin does clearly matter in modern medicine is not as a calcium regulator but as a diagnostic marker. Its value in detecting medullary thyroid carcinoma is genuinely remarkable, and monitoring calcitonin levels after surgery can reveal recurrence long before imaging catches it. The hormone’s clinical story ended up being less about what calcitonin does for you and more about what abnormal calcitonin levels tell your doctor.